Skip to main content

Table 1 Antifungal susceptibilities of major species of Candida isolatesa

From: Candidemia in a major regional tertiary referral hospital – epidemiology, practice patterns and outcomes

Antifungal MIC50 (μg/mL) MIC90 (μg/mL) MIC Range (μg/mL) %Sb %SDD/Ib %Rb %WTc
C albicans (n = 62)
 Fluconazole 0.5 2 ≤0.12–>256 95.2 1.6 3.2 93.5
 Itraconazole 0.06 0.12 ≤0.015–>16 96.7
 Posaconazole 0.015 0.06 ≤0.08–>8 96.7
 Voriconazole ≤0.008 0.03 ≤0.008–>8 93.6 3.2 3.2 93.5
 Anidulafungin ≤0.015 0.03 ≤0.015–0.25 100 0 0 98.4
 Caspofungin 0.03 0.06 0.015–4 98.4 0 1.6 98.4
 Micafungin ≤0.008 0.015 ≤0.008–2 98.4 0 1.6 98.4
 Flucytosine ≤0.06 0.25 ≤0.06–>64 96.7
 Amphotericin B 0.5 1 ≤0.12–1 100
C. glabrata (n = 82)
 Fluconazole 16 32 1–>256 92.8 7.2 97.6
 Itraconazole 1 1 0.12–>16 93.9
 Posaconazole 2 2 0.12–>8 95.1
 Voriconazole 0.5 2 0.03–>8 97.6
 Anidulafungin 0.03 0.06 ≤0.015–4 98.8 0 1.2 98.7
 Caspofungin 0.12 0.12 0.03–>8 96.4 2.4 1.2 96.3
 Micafungin 0.015 0.015 ≤0.008–4 98.8 0 1.2 98.7
 Flucytosine ≤0.06 0.12 ≤0.06–0.25 100
 Amphotericin B 1 1 0.25–2 100
C. tropicalis (n = 78)
 Fluconazole 2 64 0.5–>256 78.2 5.1 16.7 84.6
 Itraconazole 0.25 0.5 0.03–>16 96.1
 Posaconazole 0.12 0.5 0.03–4 98.7
 Voriconazole 0.12 4 ≤0.008–>8 75.6 11.5 12.8 80.8
 Anidulafungin 0.03 0.12 ≤0.015–0.5 98.7 1.3 0 98.7
 Caspofungin 0.03 0.06 0.015–2 98.7 0 1.3 98.7
 Micafungin 0.03 0.03 ≤0.008–1 98.7 0 1.3 98.7
 Flucytosine ≤0.06 0.12 ≤0.06–32 96.2
 Amphotericin B 1 1 0.25–2 100
C. parapsilosis (n = 35)
 Fluconazole 0.5 2 0.25–4 97.1 2.9 0 100
 Itraconazole 0.06 0.06 ≤0.015–0.12 100
 Posaconazole 0.03 0.06 0.015–0.12 100
 Voriconazole 0.015 0.03 ≤0.008–0.6 100 0 0 97.1
 Anidulafungin 0.5 2 0.12–2 100 0 0 100
 Caspofungin 0.25 0.5 0.06–1 100 0 0 100
 Micafungin 0.5 2 0.12–2 100 0 0 100
 Flucytosine ≤0.06 0.5 ≤0.06–1 100
 Amphotericin B 1 2 0.25–2 80.0
  1. S susceptible, SDD susceptible dose-dependent, I intermediate, R resistant, WT wild-type
  2. aMICs are only reflected for the predominant species
  3. bSusceptibilities were assessed based on CLSI species-specific clinical interpretative breakpoints [12]. Clinical breakpoints are not available for itraconazole, posaconazole, flucytosine and amphotericin B for all species and voriconazole for C. glabrata
  4. cECVs were derived from [13, 14] and [15]